PL8177 shows success as COVID-19 therapy in pre-clinical trials
The drug candidate PL8177 reduced inflammation, protected lung tissue and reduced lung fibrosis in pre-clinical models with symptoms of COVID-19.
List view / Grid view
News
Novel compound could treat type 2 diabetes without common side effects
Two molecules combined into a new substance to treat type 2 diabetes lowered blood sugar in shrew models without causing nausea, vomiting and weight loss.
CD47 blockade could work as immunotherapy across multiple diseases
Researchers have demonstrated that blocking CD47-mediated signalling in mice can enhance the speed of pathogen clearance, presenting a new potential form of immunotherapy.
Open source all-atom model of entire COVID-19 S protein released
Researchers have developed a video and model-building programme for other scientists to build full-length COVID-19 S protein models.
Potential target to control T follicular helper cells identified
A new study shows how the Bcl6 protein can regulate T follicular helper cells, presenting a target for autoimmune and infectious diseases.
N terminal domain of S protein revealed as antibody target for COVID-19
An antibody with high neutralising potency against SARS-CoV-2 that binds to the N terminal domain of the Spike protein has been identified by a team researching COVID-19 therapeutics.
Method to convert any mouse into COVID-19 model made available to researchers
Researchers who reported that delivering the human ACE2 protein into mouse airway cells creates COVID-19 models have released their findings to allow other scientists to make their own models.
Vaccine adjuvant provides long-lasting protection against HIV in monkeys
A vaccine adjuvant named 3M-052 was able to provide rhesus monkeys with protection against HIV for over a year, a new study reports.
MMR vaccine could protect against COVID-19 sepsis, paper says
Researchers have suggested that the MMR live attenuated vaccine could be used to provide non-specific protection to patients against sepsis associated with COVID-19.
Silicon-based agent could prevent progression of kidney disease and Parkinson’s
Japanese researchers have shown that a silicon-based antioxidant agent can suppress the development of kidney failure and Parkinson's disease in rodent models.
Biomarker suggests COVID-19 could cause brain injury in patients
Researchers have found that a neurofilament named NfL is heightened in COVID-19 patients who require ventilator treatment, so could serve as a biomarker for the disease.
Researchers identify link between pancreatic cancer-driving mutations
A study has shown that p53 rewires RNA splicing which leads to further activation of the KRAS oncogene, presenting a target for the progression of pancreatic cancer.
Screening reveals nelfinavir and amodiaquine combat COVID-19 in cell cultures
Researchers who screened 136 broad-spectrum antivirals identified six with the most activity against COVID-19 and an optimum combination of two to fight the virus.
Potential for Mycoplasma pneumoniae vaccine through lipoprotein removal, finds study
A new study has shown that effective and safe M. pneumoniae vaccine could be possible by removing certain lipoproteins from the bacteria.
Decoy nanoparticles show success in cell cultures as COVID-19 therapy
Researchers have developed 'nanosponges' cloaked in lung cell membranes and macrophage membranes which they found could attract and neutralise COVID-19 in cell cultures.